The causes of death in a group of patients with severe epilepsy in long term residential care over a period of 11 years were assessed and the standardised mortality rate (SMR) determined. A total of 3392 patient-years were surveyed. One hundred and thirteen deaths were recorded in the period and this represents an overall mortality rate which is almost twice the expected rate for this population (SMR = 1P9; 95% CI 1-6-2-3; p < 0-01). Most deaths were due to cancer (26%), bronchopneumonia (25%), circulatory diseases (24%), were seizure-related (12%) or due to sudden unexpected death (6%). The highest SMRs in the neoplasm sub-group were due to cancers of the pancreas (SMR = 6-2) and hepatobiliary tumours (SMR = 17*6). Twenty per cent of patients died of epilepsy or epilepsy related causes (that is accidents, during seizures, status or sudden unexpected death). One in every 480 patients died due to a sudden unexpected death. This study in a highly selected population seems to confirm suggestions that mortality rates are higher in patients with epilepsy than in the general population, but prospective studies are warranted to ascertain underlying mechanisms.
Sudden unexpected death was defined as a non-traumatic unwimessed death occurring in a patient who had been previously healthy (apart from epilepsy), or suffering from a disease which would not ordinarily be expected to produce immediate or sudden death and for whom no cause was found after necropsy examination. Death occurring during or immediately after a witnessed seizure was classified separately as a seizure related death, even in those cases where no cause for death was found after a necropsy examination.
No correlation between drug treatment and cause of death was attempted. All patients in the study were on antiepileptic therapy, the most commonly prescribed over this period were carbamazepine, phenytoin, barbiturates and sodium valproate-often in a combination of 2 or 3. In the early years of the study, however, most patients were taking barbiturates and phenytoin.
Results
A total of 3392 patient-years were surveyed. The mean age for the residents surveyed was 52 years (range 18-91 years); the male:female ratio in the group was 2:1.
Over the study period there were 1 3 deaths, which compared with 58-3 expected deaths in this population (SMR = 1*9; 95% CI 1*6 -2*3; p < 0-01). The causes of death fell into 6 main categories: neoplasms (n = 29; 26%), bronchopneumonia (n = 28; 25%), circulatory diseases (n = 27; 24%), seizure-related death (n = 13; 12%), SUD (n = 7; 6%) and accidents (n = 3; 3%). Other causes accounted for the remaining 6 deaths. The mean age at death for all patients and for individual causes is given in table 1 . Necropsy reports were available for 88 (78%) patients. All patients in the seizure-related and sudden unexpected death An overall excess mortality from neoplasms was seen in this group and this has also been noted by previous investigators" 611 although not by all.4 12 Hauser and Hesdorffer in their authoritative review of the subject estimated an overall odds ratio for tumours as 1 8,' although this figure includes CNS malignancies, which were not seen in this study, apart from one case of fibrosarcoma. A previous study of Chalfont Centre patients, both residents and ex-patients in the community, found an SMR of 1-4 for non-CNS tumours, without, however, a significant increase in tumours of any one site.6 This study, based on death certificates only, had been specifically investigating increases in cancer mortality as there had been suggestions that regular anti- (1-6-2-3)* epileptic drug-intake might increase the risk of cancer in patients with epilepsy.'4The population in this previous study differs slightly from ours in that all our patients were long term residents and the drug exposure may have been dissimilar. In addition, as our patients were kept under lifetime medical supervision and usually subjected to post mortem examination, it is possible that more tumours were diagnosed, either before or after death, than would have been the case if they were in the community. This study shows a significant increase in lung neoplasms amongst the patients, with an SMR of 3-3 although we feel that this finding should be interpreted cautiously as we have not taken into consideration the possible contribution of exposure to cigarettes. Currently, for instance, 19% of the long term residents of the centre are smokers. A similar increase in lung cancer incidence amongst patients with epilepsy has previously been noted with an odds ratio of 2 7" In the latter study the increase was restricted, however, to the period initially after diagnosis which would not be consistent with a causative role for antiepileptic drugs. A study of barbiturate-users in San Francisco did, however, demonstrate an increased SMR for lung cancer of 1 7. l There was no relationship, however, between lung cancer and duration or intensity of use of barbiturates. Friedman suggested that induction of microsomal enzymes, notably aryl-hydrocarbon hydroxylase, may convert potential carcinogens to active forms. '5 Interest in any potential increase in incidence of hepatobiliary tumours prompted the previous study at Chalfont.6 Hepatic tumours, for example, may be induced in rats by phenobarbitone.1' However, that study found no excess of hepatobiliary tumours, and no other study has demonstrated one. Our set of patients included two that died due to carcinoma of the gall bladder and one due to a cholangiocarcinoma (SMR 1 7-6), but no hepatic tumours. This is a significant increase over expected cases in this population. We have also found an excessive rate of pancreatic cancer in our patients (SMR = 6 15). High rates of pancreatic cancer have also been noted by Friedman in his study of barbiturate users but not in studies of epilepsy. 15 These findings could be artefacts of small number, and a study of the prevalence of patients with epilepsy amongst those with tumours of the biliary tree and pancreas is warranted to clarify this issue.
There is some evidence from studies of lymphoma patients that exposure to phenytoin may be a risk factor with an estimated increased risk of 2-3.16 A study of cancer incidence amongst patients with seizures found an odds ratio for lymphoma of 2-9, although the confidence limits were wide for this estimate (0-97-5). Friedman's study of phenobarbitone users also found an excess of lymphoma cases,'5 and most interest has naturally focused on the known association between phenytoin and lymphadenopathy. Of our patients, two had lymphomas and one chronic lymphatic leukaemia; the increase observed in these conditions was not significant.
The high incidence of deaths through bronchopneumonia reflects a common terminal cause in an elderly, debilitated population. In other studies of institutionalised patients, approximately 25% die a respiratory death, while in studies of patients in the community, this proportion is only about 5%. 5 Of great interest is the number of deaths in our group that could be directly attributed or associated with epilepsy. Epilepsy itself as a cause of death has been subdivided into different categories: status epilepticus, seizurerelated deaths, sudden unexpected death, and accidents. In this study death due to a seizure was used as a cause of death when the patient died during or after an attack, and no other explanation could be found at necropsy. When people died in this way without any witness they were categorised in the sudden unexpected death group rather than in the group of seizure-related death. This distinction may be arbitrary, but we nevertheless felt it was appropriate. Some clinical series of patients with epilepsy have reported proportionate rates of death of around 10% for status epilepticus5 1017 and the previous Chalfont study reported that Many previous studies have reported higher rates of accidental death than were observed in this study.35 17 20 Two patients drowned, one in a pond and the other in a bath; and one patient died from a high cervical cord contusion following a seizure. We feel that this low accident rate is due to the sheltered living environment, and may not apply to people living more independently in the community.
In summary, this study of severe long-term institutionalised patients with epilepsy seems to confirm an increase in total mortality and has suggested an increase in tumour deaths, notably of the pancreas and of the hepatobiliary systems. The cause for this is unclear, although long-term drug treatment may be relevant. Deaths directly related to epilepsy and to sudden unexpected death are also increased. Larger, prospective studies of patients in the general population are warranted.
